The Annals of thoracic surgery · 2025
Robotic-Assisted Transcatheter Aortic Valve Explantation and Aortic Valve Replacement.
СтатьяКлинический случайПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Badhwar Vinay, Darehzereshki Ali, Raikar Goya V, Mehaffey J Hunter, Daggubati Ramesh, Wei Lawrence M
Аннотация
PURPOSE: Transcatheter aortic valve replacement (TAVR) in younger patients may be complicated by premature structural valve degeneration. This report describes robotic TAVR explantation and aortic valve replacement.
DESCRIPTION: A 67-year-old woman who underwent low-risk, 23-mm balloon-expandable TAVR 4 years previously presented with severe prosthetic aortic stenosis, a drop in ejection fraction to 35%, severe type III mitral regurgitation, and symptomatic heart failure. She had scoliosis and rheumatoid arthritis, and The Society of Thoracic Surgeons predicted risk of mortality was 7.9%. Given her younger age and need for double valve replacement, transcatheter options were deferred, and she was referred for intermediate- to high-risk nonsternotomy surgical consideration.
EVALUATION: After obtaining informed consent, a right lateral transaxillary working incision facilitated robotic TAVR explantation, followed by 21-mm bioprosthetic aortic valve replacement with concomitant mitral valve replacement. The total cross-clamp time was 195 minutes. The patient recovered expectantly and was discharged home.
CONCLUSIONS: Robotic TAVR explantation and aortic valve replacement are feasible and may represent a viable future option for patients of low to intermediate surgical risk.
DESCRIPTION: A 67-year-old woman who underwent low-risk, 23-mm balloon-expandable TAVR 4 years previously presented with severe prosthetic aortic stenosis, a drop in ejection fraction to 35%, severe type III mitral regurgitation, and symptomatic heart failure. She had scoliosis and rheumatoid arthritis, and The Society of Thoracic Surgeons predicted risk of mortality was 7.9%. Given her younger age and need for double valve replacement, transcatheter options were deferred, and she was referred for intermediate- to high-risk nonsternotomy surgical consideration.
EVALUATION: After obtaining informed consent, a right lateral transaxillary working incision facilitated robotic TAVR explantation, followed by 21-mm bioprosthetic aortic valve replacement with concomitant mitral valve replacement. The total cross-clamp time was 195 minutes. The patient recovered expectantly and was discharged home.
CONCLUSIONS: Robotic TAVR explantation and aortic valve replacement are feasible and may represent a viable future option for patients of low to intermediate surgical risk.